vTv Therapeutics, Inc.:
June 2019 positive data for TTP399 as an add-on therapy to insulin therapy in a 12 week phase 1/2 trial in patients with T1D. Data-in hand from two Ph. 2 Diabetes (T2) trials: 1. Glucokinase Activator (TTP399); 2. Oral GLP-1r (TTP273). Recently licensed rights to its PDE4 program to Newsoara Biopharma to further its development in China and other Pacific Rim companies as a potential therapeutic for COPD. Results from a subgroup analysis of the STEADFAST Alzheimer’s trial presented at CTAD - moving Azeliragon forward in patients with Dementia and Diabetes.
Phase III, Phase l or ll
Central Nervous System, Diabetes
4170 Mendenhall Oaks Parkway
High Point, NC 27265
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by